Program Book - Confex
Program Book - Confex
Program Book - Confex
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Invited Speaker /Moderator Index<br />
328<br />
Hillstrom, Howard J., PhD<br />
Foot Structure, Footwear and Foot Pain -<br />
Translating Evidence into Practice . . . . . . 73<br />
Disclosure: Stride Rite, 2<br />
Knee Braces and Foot Orthosis for Knee<br />
Osteoarthritis . . . . . . . . . . . . . . . . . 73<br />
Disclosure: Stride Rite, 2<br />
Hinz, Boris, PhD<br />
Fibrosis: Novel Paradigms . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Hobday, Patricia, MD<br />
ACR/ARHP Knowledge Bowl . . . . . . . . .113<br />
Disclosure: Nothing to Disclose<br />
Hochberg, Marc, MD, MPH<br />
Disease Modifying Osteoarthritis Drugs,<br />
Glucosamine/Chondroitin and Nonpharmacologic<br />
Treatment of Osteoarthritis. 83<br />
Disclosure: Abbott Laboratories, Amgen, Astra-<br />
Zeneca Pharmaceuticals, Bioiberica S.A., Bristol<br />
Myers Squibb, Covidien, Eli Lilly, Genentech/<br />
Roche, Iroko Pharmaceuticals, Merck, EMD<br />
Serono, NiCox S.A., Novartis Pharma AG, Pfizer,<br />
Pozen, Smith and Nephew, Stryker LLC, , 5;<br />
Theralogix LLC, 1; U.S. Bone and Joint Initiative,<br />
6<br />
Hoffman, Bruce I., MD<br />
Celiac Disease: Immunopathogenesis and<br />
Clinical Spectrum Potential . . . . . . . . . 85<br />
Disclosure: Nothing to Disclose<br />
Hogaboam, Cory M., PhD<br />
Fibrosis: Novel Paradigms . . . . . . . . . . 64<br />
Disclosure: Novartis Pharmaceutical<br />
Corporation, 2<br />
Holers, V. Michael, MD<br />
The Earliest Phases of Rheumatoid Arthritis:<br />
Update on American and European Initiatives<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 81<br />
Disclosure: Nothing to Disclose<br />
Hong, Raymond, MD, MBA<br />
CORC Forum: Payment Reform Options . . 92<br />
Disclosure: Nothing to Disclose<br />
ICD-10 & HIPAA 5010 - Ready or Not…It’s<br />
Coming! . . . . . . . . . . . . . . . . . . . .116<br />
Disclosure: Nothing to Disclose<br />
Hootman, Jennifer M., ATC, PhD<br />
Introduction to Comparative Effectiveness<br />
Research Study Designs for Rheumatology<br />
Health Professionals . . . . . . . . . . . . .125<br />
Disclosure: Nothing to Disclose<br />
Policy and Environmental Strategies to Support<br />
Increased Physical Activity for Adults with<br />
Arthritis: Findings from a Centers for Disease<br />
Control/Arthritis Foundation Expert Panel .129<br />
Disclosure: Nothing to Disclose<br />
Houssiau, Frédéric A., MD, PhD<br />
Systemic Lupus Erythematosus: Lupus Nephritis<br />
. . . . . . . . . . . . . . . . . . . . . . 27, 113<br />
Disclosure: Aspreva, 5; BMS, 5; Genentech<br />
and Biogen IDEC Inc., 5; GlaxoSmithKline,<br />
5; Human Genome Sciences, Inc., 5; Roche<br />
Pharmaceuticals, 5; Serono, 5; UCB, 5<br />
2011 <strong>Program</strong> <strong>Book</strong><br />
Huber, Adam, MD<br />
Pediatrics: Dermatomyositis . . . . . . . . . 51<br />
Disclosure: Nothing to Disclose<br />
Hughes, Graham R. V., MD<br />
Antiphospholipid Syndrome . . . . . . . 55, 86<br />
Disclosure: Nothing to Disclose<br />
Huisinga, Karen, MN, ARNP<br />
Practice Potpourri . . . . . . . . . . . . . . .106<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals, 8; Pfizer Inc, 8<br />
Hummers, Laura K., MD, ScM<br />
Challenging Complications of Systemic Sclerosis<br />
. . . . . . . . . . . . . . . . . . . . . . . . .107<br />
Disclosure: Nothing to Disclose<br />
Curbside Consults - Ask the Professors . . . 59<br />
Disclosure: Actelion Pharmaceuticals US, 2;<br />
Medical & Biological Laboratories, 2; United<br />
Therapeutics, 2<br />
Scleroderma Mimics . . . . . . . . . . . . . 62<br />
Disclosure: Nothing to Disclose<br />
Humphrey, Mary Beth, MD, PhD<br />
Session I: Ontogeny and Regulation of Bone<br />
Cells . . . . . . . . . . . . . . . . . . . . . . 18<br />
Disclosure: Nothing to Disclose<br />
Hunder, Gene G., MD<br />
Temporal Arteritis . . . . . . . . . . . . . 51, 93<br />
Disclosure: Nothing to Disclose<br />
Husain, Aliya, MD<br />
Clinicopathologic Conference: A 40 Year-Old<br />
Male with Dyspnea on Exertion . . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
Husni, M. Elaine, MD, MPH<br />
Psoriatic Arthritis . . . . . . . . . . . . 55, 113<br />
Disclosure: Nothing to Disclose<br />
Spondylarthropathies: Recent Insights . . . 87<br />
Disclosure: Nothing to Disclose<br />
Hyrich, Kimme L., MD, PhD<br />
Session IV: Successes in Rheumatology<br />
Comparative Effectiveness Research. . . . . 22<br />
Disclosure: Nothing to Disclose<br />
I<br />
Inman, Robert D., MD<br />
Chronic Non-bacterial Osteomyelitis . . . .124<br />
Disclosure: Sanofi-Aventis Pharmaceutical,<br />
Merck, Abbott, Amgen-Wyeth, 5<br />
Isenberg, David A., MD<br />
Difficult to Treat Systemic Lupus Erythematosus:<br />
Case Studies . . . . . . . . . . . . . . . . . . 73<br />
Disclosure: Nothing to Disclose<br />
Ivashkiv, Lionel B., MD<br />
Session I: Ontogeny and Regulation of Bone<br />
Cells . . . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Iversen, Maura D., DPT, SD, MPH, PT<br />
Designing Exercise Prescriptions for Individuals<br />
with Arthritis and Other Comorbidities: What<br />
are the Considerations. . . . . . . . . . . .115<br />
Disclosure: Nothing to Disclose<br />
Jack, Hans-Martin, PhD<br />
Epigenetic Changes in Rheumatic Disease . 26<br />
Disclosure: Nothing to Disclose<br />
James, Judith A., MD, PhD<br />
Impact of Environmental Health on<br />
Autoimmunity . . . . . . . . . . . . . . . . . 34<br />
Disclosure: Nothing to Disclose<br />
Sjögren’s Syndrome: Not Just Dryness. . . . 23<br />
Disclosure: Nothing to Disclose<br />
James, Nadine, RN, PhD<br />
ACR Leadership Town Hall Meeting . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
ACR/ARHP Opening Lecture and Awards . . 24<br />
Disclosure: Nothing to Disclose<br />
Janisse, Dennis J., C, Ped<br />
New and Noteworthy: Nursing, Pharmacy and<br />
Pedorthics . . . . . . . . . . . . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
J<br />
Jarvis, James N., MD<br />
Career Opportunities in Rheumatology: Making<br />
a Choice . . . . . . . . . . . . . . . . . . . .123<br />
Disclosure: Genentech and Biogen IDEC Inc., 5<br />
Jimenez, Richard, MD<br />
Disability: Clinical Facts, Legal Fictions, and<br />
Practice Strategies. . . . . . . . . . . . . . . 43<br />
Disclosure: Nothing to Disclose<br />
ACR REF Memorial Lectureship: From Shulman’s<br />
Syndrome to Nephrogenic Systemic Fibrosis:<br />
Exogenous Factors and Systemic Fibrosing<br />
Disorders . . . . . . . . . . . . . . . . . . . . 57<br />
Disclosure: Nothing to Disclose<br />
Jones, Dallas, PhD<br />
New Insights into Bone Remodeling . . . . . 85<br />
Disclosure: Nothing to Disclose<br />
Jordan, Joanne M., MD, MPH<br />
Tools for Studying Joint Tissue Changes in<br />
Osteoarthritis . . . . . . . . . . . . . . . . . 34<br />
Disclosure: Algynomics, Inc., 1; Eli Lilly and<br />
Company, 5; Interleukin Genetics, Inc., 5;<br />
Johnson and Johnson, Inc., 2, 5<br />
Total Hip and Knee Replacements 2011: An<br />
Update for Rheumatologists . . . . . . . . . 74<br />
Disclosure: Algynomics, Inc., 1; Eli Lilly and<br />
Company, 5; Interleukin Genetics, Inc., 5;<br />
Johnson and Johnson, Inc., 2, 5<br />
Jorgensen, Christian, MD, PhD<br />
Stem Cell Mediated Therapies in Autoimmune<br />
Diseases . . . . . . . . . . . . . . . . . . . .118<br />
Disclosure: Nothing to Disclose<br />
K<br />
Kaeley, Gurjit S., MBBS, MRCP<br />
Musculoskeletal Ultrasonography: Basic . . 27<br />
Disclosure: equipment grant, 2<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . 17, 18<br />
Disclosure: equipment grant, 2<br />
Kafka, Shelly P., MD<br />
The Three Ps of Dermatologic and Autoimmune<br />
Disease: Pyoderma, Panniculitis and Pemphigus/<br />
Pemphigoid . . . . . . . . . . . . . . . . . . 91<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals, 9; Amgen, 9; Johnson &<br />
Johnson, 5; Lilly Pharmaceuticals, 9; Novartis<br />
Pharmaceutical Corporation, 8; Pfizer Inc, 8, 9;<br />
UCB, 5, 9